September 5, 2014OncotargetOpen Access

Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin

View Full Paper

Ask AI

Bookmark

Why the study?

Does Dihydromyricetin prevent cardiotoxicity and enhance anticancer activity in Adriamycin-treated models?

Population

Adriamycin-administrated ICR mice, primary myocardial cells, human leukemia U937 cells, and xenograft models

Comparison

Dihydromyricetin vs Adriamycin alone

Design

Preclinical

Authors

HZHong ZhuTianjin University PLPeihua LuoZhejiang Lab YFYingying FuZhejiang A & F University

Discussion

Member takes

Implication

Does not support clinical use; leaves open translation of cardioprotective and anticancer effects beyond animal models.

Structured PICO

Does Dihydromyricetin prevent cardiotoxicity and enhance anticancer activity in Adriamycin-treated models?

Population

Adriamycin-administrated ICR mice, primary myocardial cells, human leukemia U937 cells, and xenograft models

Intervention

Dihydromyricetin

Comparator

Adriamycin alone

Outcome

Cardiotoxicity (ALT, LDH, CKMB levels, toxic death, electrocardiographic changes, apoptosis) and anticancer activitysurrogate

Dihydromyricetin shows potential as a cardioprotective agent against Adriamycin-induced cardiotoxicity while potentiating its anticancer efficacy in preclinical models.

Cite This Study

Zhu et al. (2014) studied this question.

synapsesocial.com/papers/6a83a5354d653d38678dcd2f https://doi.org/10.18632/oncotarget.2410

View Full Paper

Ask AI

Bookmark

Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider